Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation.
Rheumatol Immunol Res
; 5(1): 49-56, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38571927
ABSTRACT
Background and Objectives:
Psoriasis (PsO) and psoriatic arthritis (PsA) are often undertreated and require a multidisciplinary approach. In recent years, patent expiration has allowed the introduction of tumor necrosis factor inhibitor (anti-TNF) biosimilars, which have stimulated a significant increase in the use of biological therapies. This article reports the findings of a multidisciplinary approach to achieve a consensus on the use of adalimumab in patients with PsO or PsA.Methods:
A voting panel of 36 Italian dermatologists and rheumatologists were chosen by eight Italian clinicians (the Board), to provide a consensus on the real-world management of PsO and PsA with adalimumab using the Delphi Method, comprising three survey rounds. Twelve statements were defined by the Board and submitted to the panel (rating scale 1-7).Results:
Clinicians reached a wide consensus on the effectiveness (score 6-7 67%) and long-term efficacy (6-7 100%) of adalimumab in all clinical forms of PsO and PsA, including pediatric patients (6-7 85%). Considering cost-effectiveness and safety, adalimumab is suggested as a first-line treatment in patients with enthesitis, predominant peripheral arthritis, axial involvement or associated inflammatory bowel disease (IBD) or uveitis. Adalimumab can be also considered after failure of etanercept (6-7 94%).Conclusion:
Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Rheumatol Immunol Res
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Itália